1-3 of 3
Martin Müller
Close
Sort by
Journal Articles

BCR-ABL P-Loop Deletion Detected in Imatinib-Resistant CML Patients Corresponds to Splice Variant Associated with L248V Point Mutation, Retains BCR-ABL Kinase Activity, and Responds to Dasatinib Treatment.

Nikolas von Bubnoff, MD, Philipp Erben, MD, Martin Müller, MD, Tanja Lahaye, MD, Susanne Schnittger, MD, Frank Schlegel, MD, Hubert Serve, MD, Andreas Grüneisen, MD, Rudiger Hehlmann, MD, Christian Peschel, MD, Justus Duyster, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2006) 108 (11): 2168.
https://doi.org/10.1182/blood.V108.11.2168.2168
Published: 2006
Journal Articles

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Paul La Rosée, MD, Susanne Holm-Eriksen, Thomas Ernst, MD, Heiko König, MD, Philipp Erben, MD, Martin Müller, MD, Thomas Schenk, MD, Michael Emig, MD, Anja Binckebanck, MD, Lydia Wunderle, MD, Leila Alland, MD, Peter Schuld, MD, Rüdiger Hehlmann, MD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2005) 106 (11): 497.
https://doi.org/10.1182/blood.V106.11.497.497
Published: 2005
Journal Articles

ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia

Josu de la Fuente, Kirsten Merx, E. Joanna Steer, Martin Müller, Richard M. Szydlo, Ole Maywald, Ute Berger, Rüdiger Hehlmann, John M. Goldman, Nicholas C. P. Cross, Junia V. Melo, Andreas Hochhaus, the German CML Study Group
Journal: Blood
Blood (2001) 98 (9): 2879–2880.
https://doi.org/10.1182/blood.V98.9.2879
Published: 2001